TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.59 CNY | +4.03% |
|
+5.58% | -2.22% |
| Apr. 26 | Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 29 | Dongbao Pharma's 2023 Profit Drops 26% | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 25,730 | 26,999 | 22,161 | 18,210 | 21,483 | 20,987 | - | - |
| Enterprise Value (EV) 1 | 25,487 | 26,406 | 21,296 | 17,422 | 20,528 | 18,802 | 19,121 | 17,792 |
| P/E ratio | 31.6 x | 29.1 x | 17.1 x | 11.6 x | 18.4 x | 16.3 x | 14 x | 13.1 x |
| Yield | 1.58% | 1.57% | 2.74% | 2.72% | 2.31% | 2.29% | 2.5% | 2.22% |
| Capitalization / Revenue | 9.26 x | 9.34 x | 6.78 x | 6.55 x | 6.99 x | 6.13 x | 5.4 x | 4.84 x |
| EV / Revenue | 9.18 x | 9.13 x | 6.52 x | 6.27 x | 6.67 x | 5.49 x | 4.92 x | 4.1 x |
| EV / EBITDA | 22.7 x | 19.8 x | 12.6 x | 8.88 x | - | 11.3 x | 9.82 x | 8.5 x |
| EV / FCF | 29,668,309 x | 36,984,384 x | - | - | - | - | - | - |
| FCF Yield | 0% | 0% | - | - | - | - | - | - |
| Price to Book | 5.15 x | 4.9 x | 3.59 x | 2.8 x | 2.99 x | 2.67 x | 2.35 x | 2.06 x |
| Nbr of stocks (in thousands) | 2,033,989 | 2,017,889 | 2,021,989 | 1,983,679 | 1,983,617 | 1,981,734 | - | - |
| Reference price 2 | 12.65 | 13.38 | 10.96 | 9.180 | 10.83 | 10.59 | 10.59 | 10.59 |
| Announcement Date | 4/14/20 | 1/14/21 | 1/24/22 | 2/6/23 | 1/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,777 | 2,892 | 3,268 | 2,778 | 3,075 | 3,426 | 3,888 | 4,340 |
| EBITDA 1 | 1,121 | 1,335 | 1,693 | 1,963 | - | 1,663 | 1,947 | 2,092 |
| EBIT 1 | 967.8 | 1,181 | 1,549 | 1,829 | 1,365 | 1,501 | 1,752 | 1,891 |
| Operating Margin | 34.85% | 40.82% | 47.41% | 65.82% | 44.39% | 43.8% | 45.07% | 43.57% |
| Earnings before Tax (EBT) 1 | 952.5 | 1,108 | 1,534 | 1,830 | 1,366 | 1,503 | 1,754 | 1,896 |
| Net income 1 | 811.2 | 929.9 | 1,308 | 1,582 | 1,168 | 1,299 | 1,507 | 1,623 |
| Net margin | 29.21% | 32.15% | 40.03% | 56.93% | 37.97% | 37.91% | 38.76% | 37.39% |
| EPS 2 | 0.4000 | 0.4600 | 0.6400 | 0.7900 | 0.5900 | 0.6500 | 0.7543 | 0.8100 |
| Free Cash Flow | 859.1 | 714 | - | - | - | - | - | - |
| FCF margin | 30.93% | 24.69% | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | 76.65% | 53.47% | - | - | - | - | - | - |
| FCF Conversion (Net income) | 105.9% | 76.78% | - | - | - | - | - | - |
| Dividend per Share 2 | 0.2000 | 0.2100 | 0.3000 | 0.2500 | 0.2500 | 0.2425 | 0.2650 | 0.2350 |
| Announcement Date | 4/14/20 | 1/14/21 | 1/24/22 | 2/6/23 | 1/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 812.9 | 887.5 | 500 | 711.5 | 679.4 | 665.4 | 701 | 725.2 | 983.9 | 591.4 | 751.1 | 875 | 855 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 289.5 | 980.4 | 403.4 | 259.4 | 185.7 | 289.6 | 272.9 | 316.5 | 486.1 | 238.9 | 291.5 | 354.2 | 361.7 |
| Operating Margin | 35.61% | 110.47% | 80.67% | 36.46% | 27.33% | 43.53% | 38.93% | 43.65% | 49.4% | 40.39% | 38.81% | 40.48% | 42.31% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | 214.7 | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | 36.3% | - | - | - |
| EPS 2 | 0.1200 | 0.4100 | 0.1800 | 0.1100 | 0.0900 | 0.1300 | 0.1100 | 0.1400 | 0.2100 | 0.1100 | 0.1450 | 0.1600 | 0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 1/24/22 | 4/28/22 | 8/30/22 | 10/30/22 | 2/6/23 | 4/26/23 | 8/21/23 | 10/30/23 | 1/29/24 | 4/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 243 | 593 | 865 | 788 | 954 | 2,184 | 1,865 | 3,195 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 859 | 714 | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 16.6% | 17.7% | 22.1% | 24.5% | 17.1% | 17.2% | 17.7% | 16.5% |
| ROA (Net income/ Total Assets) | 15% | 16.8% | 21.6% | 23.8% | - | 16.4% | 16.8% | 15.9% |
| Assets 1 | 5,407 | 5,532 | 6,062 | 6,635 | - | 7,935 | 8,996 | 10,219 |
| Book Value Per Share 2 | 2.460 | 2.730 | 3.060 | 3.280 | 3.620 | 3.970 | 4.510 | 5.140 |
| Cash Flow per Share 2 | 0.5700 | 0.5900 | 0.5600 | 0.4300 | 0.4300 | 0.6400 | 0.8000 | 0.8700 |
| Capex 1 | 293 | 478 | 580 | 492 | 348 | 266 | 315 | 452 |
| Capex / Sales | 10.55% | 16.54% | 17.76% | 17.69% | 11.31% | 7.77% | 8.1% | 10.41% |
| Announcement Date | 4/14/20 | 1/14/21 | 1/24/22 | 2/6/23 | 1/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.59
CNY
Average target price
15.27
CNY
Spread / Average Target
+44.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.22% | 2.9B | |
| -4.68% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 600867 Stock
- Financials Tonghua Dongbao Pharmaceutical Co., Ltd.
